Bicara Therapeutics Inc. 4

CFO Jennifer Larson received an equity compensation grant of 285,000 stock options for Bicara Therapeutics Inc. common stock at a $24.63 exercise price.

On August 12, 2026, Bicara Therapeutics Inc. Chief Financial Officer Jennifer Larson received a grant of stock options to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, with 25% of the options vesting on August 12, 2027 and the remaining 75% vesting in twelve equal quarterly installments thereafter, contingent on continued service. This award represents a new compensatory grant rather than an open-market transaction, and increases Larson’s derivative interest in the company to 285,000 options; assuming full vesting and using the $24.63 exercise price as a proxy for current value, the option grant has a notional value of approximately $7.0 million and would translate into a similar order of magnitude for her potential equity stake upon exercise.

Filing Facts

CIK

2023658

Ticker

BCAX

Form

4

Source Type

fda

Accession

0001470831-26-000819

Alert Tier

7